Nurix Therapeutics to Participate in Upcoming Investor Conferences
August 31, 2022 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer
August 03, 2022 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced...
Nurix Therapeutics Announces $40 Million Registered Direct Offering
July 08, 2022 08:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced...
Nurix Therapeutics Announces $55 Million Registered Direct Offering
July 07, 2022 17:03 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, July 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced...
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update
July 07, 2022 16:05 ET
|
Nurix Therapeutics, Inc.
NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain B-cell malignancies NX-1607 IND cleared FDA...
Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
June 30, 2022 08:00 ET
|
Nurix Therapeutics, Inc.
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical...
Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress
June 10, 2022 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs,...
Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
June 03, 2022 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, June 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs,...
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
May 26, 2022 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has...
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas
May 17, 2022 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that...